CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics is supported by compelling early evidence that CTX310 can deliver durable one-time ANGPTL3 editing, with a mean 78.6% reduction at one year and stable effects across 15 patients, suggesting meaningful differentiation versus recurring ASO or siRNA dosing. The safety profile also appears manageable, as reported liver enzyme elevations were transient, did not recur with extended follow-up, and no serious safety events were seen, which reduces a key development risk for an in vivo gene-editing program. Beyond CTX310, the investment case is reinforced by Casgevy’s commercialization potential and the company’s broader pipeline in immuno-oncology, cardiovascular disease, and type 1 diabetes, with the base case assuming Casgevy exceeds $1B in global sales by 2030.

CRISPR Therapeutics is weighed down by a highly uncertain CRISPR/Cas9 intellectual-property position, heavy dependence on third-party rights, and meaningful clinical risk across a broad pipeline where failures could erode confidence in the platform itself. Although CTX310 has shown reductions in ANGPTL3, LDL-C, and triglycerides, the data are inconsistent and based on small cohorts, with durability and dose-response variability raising doubts about reproducibility and long-term commercial value. The bear thesis is further pressured by reliance on partners such as Vertex and Bayer, alongside likely need for additional equity financing, which could dilute shareholders if Casgevy sales do not accelerate and earlier-stage programs underperform.